ASND in the 13F filings
Ascendis Pharma A · CUSIPs 04351P101, K08588103
- Quarter end
- 31 Dec 2024
- the date the book describes
- Filed
- 5 Nov 2026
- latest of these filings; the earliest 31 Jan 2025
- Managers listing it
- 11
- at least, of 95 tracked, among listed positions
- Comparable managers
- 94
- filed both Q3 2024 and Q4 2024; 11 listed it in both
- Shares listed
- 19,061,166
- combined, among listed positions
- Reported value
- $2.6bn
- combined, at the quarter end
Among the 94 comparable managers: 6 buyers (opened or added shares) and 7 sellers (trimmed or exited), at least, among listed positions. Their net change in shares is not known from listed positions, because at least one of them lists it in only one of the two quarters.
Managers listing ASND in Q4 2024
11 of 11 holders
Largest increases and reductions, by shares
Increases
- Janus Henderson Group Ltdexisting position · 4,380,382 shares now+193,688
- T. Rowe Price Associates Incexisting position · 2,283,207 shares now+162,079
- Woodline Partners LPexisting position · 317,642 shares now+82,624
- Artisan Partners LPexisting position · 4,450,420 shares now+39,309
- Point72 Asset Management LPexisting position · 503,669 shares now+8,122
Reductions
- Fidelity (FMR LLC)existing position · 4,728,647 shares now-179,199
- Voloridge Investment Management LLCexisting position · 298,996 shares now-98,017
- Schonfeld Strategic Advisors LLCexisting position · 138,593 shares now-89,932
- Acadian Asset Management LLCexisting position · 72,059 shares now-48,835
- Moore Capital Management LPexisting position · 20,000 shares now-20,000
New positions and exits
New (0)
No new position among listed positions.
Exited (2)
- Baillie Gifford & Cowas $3.2m
- Farallon Capital Management LLCwas $209k
Ownership over time
Tracked managers listing it, at least.
| Quarter | Holders | Reported value | Buyers | Sellers |
|---|---|---|---|---|
| Q2 2017 | 1 | $2.1m | n.a. | n.a. |
| Q3 2017 | 2 | $4.7m | n.a. | n.a. |
| Q4 2017 | 1 | $4.8m | n.a. | n.a. |
| Q1 2018 | 6 | $362m | n.a. | n.a. |
| Q2 2018 | 4 | $310m | n.a. | n.a. |
| Q3 2018 | 3 | $359m | n.a. | n.a. |
| Q4 2018 | 4 | $638m | n.a. | n.a. |
| Q1 2019 | 8 | $1.7bn | n.a. | n.a. |
| Q2 2019 | 8 | $1.9bn | n.a. | n.a. |
| Q3 2019 | 8 | $1.7bn | n.a. | n.a. |
| Q4 2019 | 12 | $2.8bn | n.a. | n.a. |
| Q1 2020 | 9 | $2.3bn | n.a. | n.a. |
| Q2 2020 | 8 | $3.2bn | n.a. | n.a. |
| Q3 2020 | 9 | $4.1bn | n.a. | n.a. |
| Q4 2020 | 12 | $4.5bn | n.a. | n.a. |
| Q1 2021 | 10 | $3.4bn | n.a. | n.a. |
| Q2 2021 | 10 | $3.4bn | n.a. | n.a. |
| Q3 2021 | 10 | $4.5bn | n.a. | n.a. |
| Q4 2021 | 11 | $3.7bn | n.a. | n.a. |
| Q1 2022 | 10 | $3.3bn | n.a. | n.a. |
| Q2 2022 | 9 | $2.5bn | n.a. | n.a. |
| Q3 2022 | 12 | $2.7bn | n.a. | n.a. |
| Q4 2022 | 12 | $3.0bn | n.a. | n.a. |
| Q1 2023 | 9 | $2.6bn | n.a. | n.a. |
| Q2 2023 | 8 | $1.9bn | n.a. | n.a. |
| Q3 2023 | 8 | $2.0bn | n.a. | n.a. |
| Q4 2023 | 11 | $2.8bn | 5 | 7 |
| Q1 2024 | 16 | $3.4bn | 10 | 6 |
| Q2 2024 | 14 | $2.8bn | 8 | 7 |
| Q3 2024 | 15 | $3.1bn | 11 | 5 |
| Q4 2024 | 11 | $2.6bn | 6 | 7 |
| Q1 2025 | 13 | $3.2bn | 7 | 6 |
| Q2 2025 | 11 | $3.2bn | 5 | 6 |
| Q3 2025 | 15 | $3.7bn | 6 | 8 |
| Q4 2025 | 14 | $3.7bn | 16 | 14 |
| Q1 2026 | 10 | $3.1bn | 7 | 25 |
| Q2 2026 | 12 | $4.3bn | 19 | 9 |
Compare with…
Holders over time, buyers and sellers, and the managers holding both, side by side for up to four stocks.
ASND and LLY →ASND and JNJ →ASND and VRTX →Choose a stock to compare with ASND →
How much of the picture this is
A 13F is a manager’s long US-listed equity book at a quarter end, filed up to 45 days later. It shows no shorts, cash, bonds or performance, and it is never today’s portfolio. Large books are listed to their largest positions, so a manager missing from this table may still hold a small position below that line. These are 95 tracked managers, not the institutional market.
Which funds own ASND, latest filings →Back to the 13F Explorer →